139 related articles for article (PubMed ID: 38756644)
1. Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study.
Li RR; Zhou HJ; Zeng DY; Jiang SF; Liu W; Frühling P; Liu ZY
J Gastrointest Oncol; 2024 Apr; 15(2):612-629. PubMed ID: 38756644
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study.
Chida K; Kotani D; Nakamura Y; Kawazoe A; Kuboki Y; Shitara K; Kojima T; Taniguchi H; Watanabe J; Endo I; Yoshino T
Ther Adv Med Oncol; 2021; 13():17588359211009143. PubMed ID: 33959196
[TBL] [Abstract][Full Text] [Related]
3. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
[TBL] [Abstract][Full Text] [Related]
4. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
[TBL] [Abstract][Full Text] [Related]
5. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M
ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196
[TBL] [Abstract][Full Text] [Related]
6. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
[TBL] [Abstract][Full Text] [Related]
7. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Satake H; Kato T; Oba K; Kotaka M; Kagawa Y; Yasui H; Nakamura M; Watanabe T; Matsumoto T; Kii T; Terazawa T; Makiyama A; Takano N; Yokota M; Okita Y; Matoba K; Hasegawa H; Tsuji A; Komatsu Y; Yoshino T; Yamazaki K; Mishima H; Oki E; Nagata N; Sakamoto J
Oncologist; 2020 Dec; 25(12):e1855-e1863. PubMed ID: 32666647
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Takahashi T; Yamazaki K; Oki E; Shiozawa M; Mitsugi K; Makiyama A; Nakamura M; Ojima H; Kagawa Y; Matsuhashi N; Okuda H; Asayama M; Yuasa Y; Shimada Y; Manaka D; Watanabe J; Oba K; Yoshino T; Yoshida K; Maehara Y
ESMO Open; 2021 Apr; 6(2):100093. PubMed ID: 33744811
[TBL] [Abstract][Full Text] [Related]
10. An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer.
Hsieh MC; Rau KM; Lin SE; Liu KW; Chiu CC; Chen CI; Song LC; Chen HP
Front Oncol; 2022; 12():867546. PubMed ID: 35664763
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
Martínez-Lago N; Chucla TC; De Castro BA; Ponte RV; Rendo CR; Rodriguez MIG; Diaz SS; Suarez BG; de la Cámara Gomez J; Fernández FB; Salvador MM; Lopez MR
Sci Rep; 2022 Aug; 12(1):14612. PubMed ID: 36028552
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
[TBL] [Abstract][Full Text] [Related]
13. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
[TBL] [Abstract][Full Text] [Related]
14. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
15. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K
Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
[TBL] [Abstract][Full Text] [Related]
17. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.
Zou J; Wang Y; Xu J; Li J; Wang T; Zhang Y; Bai Y
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202064
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.
Yoshino T; Oki E; Nozawa H; Eguchi-Nakajima T; Taniguchi H; Morita S; Takenaka N; Ozawa D; Shirao K
ESMO Open; 2018; 3(5):e000411. PubMed ID: 30167332
[TBL] [Abstract][Full Text] [Related]
20. Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis.
Yoshino T; Taieb J; Kuboki Y; Pfeiffer P; Kumar A; Hochster HS
Ther Adv Med Oncol; 2023; 15():17588359221146137. PubMed ID: 36743525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
